Pipeline: New therapies to come for debilitating eye diseases

Article

New drug from Gensight Biologics hits pipeline

GenSight Biologics has developed a therapy for Leber hereditary optic neuropathy (LHON), called Lumevoq. The drug has been submitted for approval in Europe, and the company plans to submit for U.S. Food & Drug Administration approval in late 2021.

Dr. Gilly explains the mechanism of action for Lumevoq and provides a look into the GenSight Biologics pipeline for the future.

Related: Myopia control data and whats to come with Dr. Noel Brennan

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Subscribe Now!
Recent Videos
Erin Tomiyama, OD, PhD, FAAO, offers actionable advice for myopia management and perspective for practitioners ready to refine their approach.
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Mitch Ibach, OD, FAAO, details the importance to unveiling the underlying cause of dry eye in a CCS 2025 presentation.
Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, ponders what she would like to see develop as both a researcher and a clinician in the dry eye space.
Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, discussed research that utilized IQVIA longitudinal prescription claims data from September through November 2023, coinciding with Miebo's FDA approval in September.
Dr Julie Poteet reports on patient-reported outcomes using lipid-containing artificial tear
Susana Marcos, PhD, outlines a presentation she gave at ARVO 2025 on a unique utilization of optical coherence tomography.
Karl Stonecipher ASCRS 2025
AnnMarie Hipsley, DPT, PhD, at ASCRS 2025
Neda Shamie, MD; Selina McGee, OD, FAAO, Dipl ABO; and Jacob Lang, OD, FAAO; provided their insights during CIME 2025 on May 4.
Related Content
Doctor listening to patient Image credit: AdobeStock/motortion

Cohort study evaluates association between POAG and mental health

Lynda Charters
June 10th 2025
Article
You and Eye by Optometry Times with host Miriam Korik, OD

You and Eye: Myopia cannot be viewed as a specialty in today's practice setting

Miriam Korik, OD;Justin Kwan, OD, FAAO;Emily Kaiser Maharjan, Assistant Managing Editor
October 18th 2024
Podcast
European Commission approves low-dose atropine eye drop Ryjunea, Santen announces - Image credit: ©artjazz—stock.adobe.com

European Commission approves low-dose atropine eye drop Ryjunea, Santen announces

Hattie Hayes
June 5th 2025
Article
You and Eye: Mastering myopia management - with Justin Kwan, OD, FAAO

You and Eye: Mastering myopia management - with Justin Kwan, OD, FAAO

Miriam Korik, OD;Justin Kwan, OD, FAAO;Emily Kaiser Maharjan, Assistant Managing Editor
October 9th 2024
Podcast
Woman administering eye drops Image credit: AdobeStock/AndreyPopov

Bausch + Lomb launch Blink Nourish Lubricating eye drops and Blink Boost Lubricating eye drops in the US for dry eye

Jordana Joy, Associate Editor
June 4th 2025
Article
iVeena submits IND to FDA for a phase 2 clinical trial for pediatric myopia ©OHishi_Foto—stock.adobe.com

iVeena submits IND to FDA for a phase 2 clinical trial for pediatric myopia

Emily Kaiser Maharjan, Assistant Managing Editor
June 4th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.